Form 4: Acrivon Therapeutics Director Charles Baum Granted Stock Options

Acrivon Therapeutics, Inc. Director Charles M. Baum was granted 20,275 stock options with an exercise price of $1.2 per share, vesting prior to the next annual stockholders' meeting.

Summary

• Charles M. Baum, a Director of Acrivon Therapeutics, Inc. (ACRV), was granted 20,275 stock options.
• The options have an exercise price of $1.2 per share.
• The transaction date for this grant was June 13, 2025.
• The options are exercisable until June 12, 2035.
• The shares underlying the option will vest on the date immediately preceding the Issuer's next annual meeting of stockholders, contingent on Mr. Baum's continuous service.
• Following this transaction, Mr. Baum directly beneficially owns 20,275 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of continued alignment between management/board and shareholder interests, and a standard compensation practice. It doesn't indicate any negative operational or financial issues.

Positives

• The grant of stock options aligns the director's interests with shareholder value, as the options gain value if the stock price increases above the exercise price.
• This represents a standard form of equity compensation for a director, indicating continued commitment to the company.

Negatives

• No direct negatives are apparent from this Form 4 filing, as it reports a standard equity grant.

Risks

• The vesting of the options is subject to the reporting person's continuous service through the applicable vesting date, meaning the options could be forfeited if service ceases.

Future Outlook

The granted stock options are set to vest on the date immediately preceding Acrivon Therapeutics' next annual meeting of stockholders, provided Charles M. Baum maintains continuous service.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, a common practice across the biotechnology and pharmaceutical industries to align executive and director incentives with long-term company performance and shareholder interests.

Comparison to Industry Standards

• The grant of 20,275 stock options to a director with an exercise price of $1.2 is a standard form of non-cash compensation.
• While specific comparable companies or projects are not detailed in this filing, such grants are typical in the biotech sector for board members, often tied to performance or continued service, similar to practices seen at companies like Moderna or BioNTech for their non-executive directors, though the specific number and value would vary based on company size and compensation philosophy.

Corporate Governance

Related Party Transactions

• The stock option grant to Charles M. Baum, a Director of Acrivon Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's incentives with shareholder interests, as the options gain value with stock price appreciation. It represents a form of dilution if exercised, but is a common compensation practice.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The Power of Attorney streamlines compliance for the director, potentially reducing administrative burden on management related to SEC filings.

Next Steps

• The shares subject to the option will vest on the date immediately preceding the Issuer's next annual meeting of stockholders.
• Charles M. Baum must maintain continuous service through the vesting date to receive the shares.

Key Dates

Recommendation

Keywords

Acrivon Therapeutics, ACRV, Stock Option, Director Compensation, SEC Form 4, Equity Grant, Beneficial Ownership, Charles M. Baum